Use of Chimeric Antigen Receptor T Cells as a Potential Therapeutic for Glioblastoma

Use of Chimeric Antigen Receptor T Cells as a Potential Therapeutic for Glioblastoma SCIENCE TIMES 6. Gilard V, Djoubairou BO, Lepetit A, et al. progressed. In this study, the patient was reported. This response continued Small versus large catheters for ventriculostomy in the underwent surgical resection of 3 out of for 7.5 mo after initiation of CAR T-cell management of intraventricular hemorrhage. World 5 progressive tumors. A Rickham catheter therapy. However, the tumor eventually Neurosurg. 2017;97:117-122. was placed into the resection cavity of one recurred at 4 intracranial sites that were 7. Honeybul S, Ho KM, Gillett G. Outcome following decompressive hemicraniectomy for malignant of the tumors through which the patient different and non-adjacent to initial cerebral infarction: ethical considerations. Stroke. received 6 cycles of autologous CAR T- tumors. 2015;46(9):2695-2698. 6 3 cells (2–10 × 10 cells/infusion) that had The paper by Brown et al provides been modified to target the IL13Rα2. proof of concept for utilizing CAR T- The patient received 10 further doses cells in GBM. The route of delivery was Use of Chimeric Antigen through an intraventricular catheter after 2 shown to be important as intracavitary nonresected lesions continued to progress infusion appeared to act locally while Receptor T Cells as a and 2 new lesions appeared. Cerebrospinal intraventricular http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Neurosurgery Oxford University Press

Use of Chimeric Antigen Receptor T Cells as a Potential Therapeutic for Glioblastoma

Loading next page...
 
/lp/ou_press/use-of-chimeric-antigen-receptor-t-cells-as-a-potential-therapeutic-bpRqcJVQRm
Publisher
Oxford University Press
Copyright
Copyright © 2017 by the Congress of Neurological Surgeons
ISSN
0148-396X
eISSN
1524-4040
D.O.I.
10.1093/neuros/nyx105
Publisher site
See Article on Publisher Site

Abstract

SCIENCE TIMES 6. Gilard V, Djoubairou BO, Lepetit A, et al. progressed. In this study, the patient was reported. This response continued Small versus large catheters for ventriculostomy in the underwent surgical resection of 3 out of for 7.5 mo after initiation of CAR T-cell management of intraventricular hemorrhage. World 5 progressive tumors. A Rickham catheter therapy. However, the tumor eventually Neurosurg. 2017;97:117-122. was placed into the resection cavity of one recurred at 4 intracranial sites that were 7. Honeybul S, Ho KM, Gillett G. Outcome following decompressive hemicraniectomy for malignant of the tumors through which the patient different and non-adjacent to initial cerebral infarction: ethical considerations. Stroke. received 6 cycles of autologous CAR T- tumors. 2015;46(9):2695-2698. 6 3 cells (2–10 × 10 cells/infusion) that had The paper by Brown et al provides been modified to target the IL13Rα2. proof of concept for utilizing CAR T- The patient received 10 further doses cells in GBM. The route of delivery was Use of Chimeric Antigen through an intraventricular catheter after 2 shown to be important as intracavitary nonresected lesions continued to progress infusion appeared to act locally while Receptor T Cells as a and 2 new lesions appeared. Cerebrospinal intraventricular

Journal

NeurosurgeryOxford University Press

Published: May 1, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off